ProQR Therapeutics N.V. (PRQR) is a Netherlands-based company that operates as a biopharmaceutical firm, focusing on the development and commercialization of treatments for rare, genetic diseases. The company takes a unique approach to tackling genetic disorders by correcting RNA mutations through a process called RNA repair. This process aims to correct the genetic fault causing the disease, with the hope of providing a one-time treatment.
Founded in 2012 by Daniel de Boer, a father inspired by his son's diagnosis of cystic fibrosis, ProQR Therapeutics has grown into a leading entity within the genetic therapeutics industry. As of now, it has several products in its pipeline addressing various disorders such as Leber’s congenital amaurosis 10 (LCA10), Usher syndrome, and dystrophic epidermolysis bullosa, among others.
The company's lead product candidate, sepofarsen (QR-110), is being developed for Leber's congenital amaurosis, a rare inherited retinal disease that affects infants and children, leading to vision loss. In Phase 1/2 and Phase 2/3 clinical trials, sepofarsen demonstrated substantial improvement in vision in treated patients, reflecting the potential of ProQR's RNA-targeting therapeutics.
Another key candidate in their pipeline is QR-421a for Usher syndrome and retinitis pigmentosa, diseases characterized by the progressive loss of both hearing and vision. This therapy is in the early stages of clinical development, permitting the testing of its safety and efficacy.
Expanding its focus, ProQR is developing Q-101, an RNA-based therapy targeting cystic fibrosis, the disease that initially inspired the company's foundation. This condition causes severe damage to the lungs and digestive system, affecting around 70,000 people globally.
ProQR Therapeutics N.V., listed on the NASDAQ (PRQR), continues to leverage cutting-edge RNA technology to create a transformative impact on patients' lives afflicted by severe genetic disorders. The passion and ambition behind the company have been recognized through partnerships with leading institutions and pharmaceutical companies. Determined to make a difference, ProQR carries its mission of breaking new grounds within genetic diseases by addressing the underlying cause with transformative RNA medicines.